Prelude Corp

About Prelude Corp

Prelude Corporation (PreludeDx) operates as a personalized diagnostics company with a focus on providing actionable tools for managing early-stage breast cancer. Founded in 2009, the company emerged from technology licensed from the University of California, San Francisco (UCSF), following initial biomarker data presented in 2006. The development of its core technology was supported by research funding from the National Cancer Institute.

The company is led by President and CEO, Daniel Forche, who brings over two decades of experience in the diagnostics industry, particularly in oncology, having worked with companies like Abbott Labs and LabCorp. His career, and personal connection to cancer diagnoses within his family, has fueled his focus on personalized medicine. Troy Bremer, a co-founder and the Chief Scientific Officer, has been with PreludeDx since its inception, applying his expertise in machine learning and biostatistics to diagnostic development.

PreludeDx's business model centers on the sale of its diagnostic tests to physicians and cancer centers. Revenue is generated by providing these tests, which are then used to inform treatment decisions. The company has established agreements with various healthcare payers and cost containment groups to expand access to its tests for a wider patient population. PreludeDx operates in the precision medicine market, specifically targeting early-stage breast cancer diagnostics. Its primary clients are physicians, surgeons, and oncologists who treat patients with breast cancer.

The company's flagship product is the DCISionRT test, designed for patients with Ductal Carcinoma in Situ (DCIS), also known as Stage 0 breast cancer. This diagnostic tool analyzes a patient's tumor tissue, examining seven protein biomarkers along with four clinicopathologic risk factors, to provide a personalized recurrence risk score. The test's unique selling point is its ability to predict not only the 10-year risk of recurrence but also the potential benefit of adjuvant radiation therapy (RT) after breast-conserving surgery. This helps patients and their doctors make more informed, shared decisions, potentially avoiding overtreatment or undertreatment. In January 2025, the FDA granted Breakthrough Device designation for the DCISionRT test. The company is also expanding its portfolio with AidaBreast, a multi-omic assay for Stage I and IIa invasive breast cancer.